Physician profile
John Moore
NPI 1255542361
$10,468.98
in general payments reported to CMS, 2019-2025
43 companies · $1,306 in 2025
The $1,306 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,142 · 2020: $1,032 · 2021: $1,495 · 2022: $1,788 · 2023: $1,271 · 2024: $1,435 · 2025: $1,306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,013.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,012.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,203.06 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,551.27 | 2021-2025 | |
| Pfizer INC. | $1,221.98 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $878.69 | 2019-2024 | Farxiga, Breztri |
| Amgen INC. | $486.17 | 2019-2025 | Evenity, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $408.73 | 2019-2023 | Jardiance |
| Allergan, INC. | $370.93 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $303.91 | 2019-2023 | |
| Glaxosmithkline, LLC. | $273.88 | 2021-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $257.46 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $211.94 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $183.71 | 2019-2023 | Verquvo, Belsomra |
| Esperion Therapeutics, INC. | $178.71 | 2020-2022 | |
| Boston Scientific Corporation | $177.40 | 2019-2025 | Watchman Flx, General - Pain Management |
| Dexcom, INC. | $156.33 | 2023-2025 | Dexcom G6 Transmitter |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.